Make a Gift
A gift to the Division of General Surgery helps us
discover
new treatments and cures.
Robert S. Warren, M.D.
Professor and Chief, Section of Surgical Oncology
Director, Surgical Oncology Lab
Contact Information
San Francisco, California 94143-1932
New Patient Coordinator Telephone: (415) 353-9888
Academic Telephone: (415) 353-9294
Fax: (415) 353-9296
robert.warren@ucsfmedctr.org
Education
- 1969-71, University of Minnesota B.A., Physiology, Magna Cum Laude
- 1976-80, University of Minnesota Medical School, Minneapolis M.D.
Residencies
- 1980-81, University of Minnesota, Intern, Surgery
- 1981-88, University of Minnesota, Resident, Surgery
Fellowships
- 1980-81, University of Minnesota, Postdoctoral Fellow, Surgery
- 1981-88, University of Minnesota, Postdoctoral Fellow, Surgery
- 1983-86, Memorial Sloan-Kettering Cancer Center, Fellow, Oncology Research
- 1983-86, Memorial Sloan-Kettering Cancer Center, Postdoctoral Fellow, Oncology
Board Certification
- American Board of Surgery, 1989
Program Affiliations
- Surgical Oncology Program
- Surgical Oncology Laboratory
- UCSF Helen Diller Family Comprehensive Cancer Center
- UCSF Department of Surgery
Clinical Expertise
- Liver Cancer
- Benign Neoplasms of the Gastrointestinal Tract
- Bile Duct Cancer
- Colorectal liver metastases
- Gallbladder cancer
- Gastrointestinal Stromal Tumors (GIST)
- Pancreatic Cancer
- Retroperitoneal Neoplasms
- Small Intestine Cancer
- Stomach (Gastric) Cancer
- Whipple Procedure
Biography
Robert S. Warren, M.D. is a Professor of Surgery and Chief of the Surgical Oncology Program. Dr. Warren is a specialist in gastrointestinal and liver cancer. He earned a medical degree at the University of Minnesota, where he completed a general surgery residency. After completing an oncology research fellowship at Memorial Sloan-Kettering Cancer Center in New York, he was an associate physician at Rockefeller University in New York. A board-certified surgeon, Dr. Warren joined UCSF Medical Center in 1988. His research focuses on the biology of colorectal cancer and how it spreads.
Dr. Warren is involved in clinical and laboratory research, which has centered on the biology of colorectal cancer metastasis that includes Vascular Endothelial Growth Factor (VEGF), Insulin-Like Growth Factors and Their Binding Proteins AS Modulators of Growth of Colorectal Cancer Metastases and Cytogenetics of Colorectal Cancer Metastasis. The laboratory work focuses on two areas: 1) autocrine growth factors and angiogenesis in colorectal cancer 2) molecular features which predict clinical outcome in primary and metastatic colorectal cancer.
Research Summary
- Biology of colorectal cancer metastasis
- Molecular features which predict clinical outcome in primary and metastatic colorectal cancer
- Autocrine growth factors and angiogenesis in colorectal cancer
- Vascular Endothelial Growth Factor (VEGF) Hypoxia and Colon Cancer
- Insulin-Like Growth Factors and Their Binding Proteins As Modulators of Growth of Colorectal Cancer Metastases
- Cytogenetics of Colorectal Cancer Metastasis
Selected Publications
- Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V, Randazzo F, Gundel R, Warren RS, Escobedo J, Aukerman SL, Taylor RN and Fantl WJ. Beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 3145-53, 2003.
- Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP and Waldman FM. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res. 1791-7, 2005.
- Arvold ND, Guha N, Wang D, Matli M, Deen DF, Warren RS and Haas-Kogan DA. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. Int J Radiat Oncol Biol Phys. 207-12, 2005.
- Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C and Mayer RJ. Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481). J Clin Oncol. 1395-403, 2006.
- LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, and Mayo LD. Nutlin3 Blocks Vascular Endothelial Growth Factor Induction by Preventing the Interaction between Hypoxia Inducible Factor 1 and Hdm2. Cancer Res. 450-454, 01/2007.
